Immunovant Management
Management criteria checks 4/4
Immunovant's CEO is Pete Salzmann, appointed in Jun 2019, has a tenure of 4.92 years. total yearly compensation is $5.82M, comprised of 10.7% salary and 89.3% bonuses, including company stock and options. directly owns 0.27% of the company’s shares, worth $12.02M. The average tenure of the management team and the board of directors is 2.6 years and 4.6 years respectively.
Key information
Pete Salzmann
Chief executive officer
US$5.8m
Total compensation
| CEO salary percentage | 10.7% |
| CEO tenure | 4.9yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.6yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Apr 19
Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Apr 04Immunovant: An Intriguing And Developing Story
Jan 25Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate
Jan 12We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Sep 28Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Jun 14Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Mar 08We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Nov 06Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset
Oct 17Immunovant stock down on raising $75M though equity capital
Oct 04We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Aug 06Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Apr 06We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Jun 20Immunovant EPS beats by $0.04
Jun 01argenx rise even as Immunovant pauses the trial for anti-FcRn therapy
Feb 03Immunovant slips 7% on voluntary hold of IMVT-1401 dosing
Feb 02Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management
Jan 14Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?
Dec 30Immunovant (IMVT) Investor Presentation - Slideshow
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$243m |
| Sep 30 2023 | n/a | n/a | -US$255m |
| Jun 30 2023 | n/a | n/a | -US$245m |
| Mar 31 2023 | US$6m | US$625k | -US$211m |
| Dec 31 2022 | n/a | n/a | -US$199m |
| Sep 30 2022 | n/a | n/a | -US$177m |
| Jun 30 2022 | n/a | n/a | -US$167m |
| Mar 31 2022 | US$6m | US$600k | -US$157m |
| Dec 31 2021 | n/a | n/a | -US$138m |
| Sep 30 2021 | n/a | n/a | -US$128m |
| Jun 30 2021 | n/a | n/a | -US$111m |
| Mar 31 2021 | US$15m | US$567k | -US$107m |
| Dec 31 2020 | n/a | n/a | -US$100m |
| Sep 30 2020 | n/a | n/a | -US$79m |
| Jun 30 2020 | n/a | n/a | -US$73m |
| Mar 31 2020 | US$9m | US$361k | -US$66m |
Compensation vs Market: Pete's total compensation ($USD5.82M) is about average for companies of similar size in the US market ($USD6.70M).
Compensation vs Earnings: Pete's compensation has been consistent with company performance over the past year.
CEO
Pete Salzmann (55 yo)
4.9yrs
Tenure
US$5,819,818
Compensation
Dr. Peter Salzmann, also known as Pete, M.D., M.B.A. is the Chief Executive Officer of Immunovant, Inc. since June 2019 and has been its Director since October 2019. Dr. Salzmann is an Independent Director...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairperson of the Board | 4.9yrs | US$2.49m | 0.083% $ 3.7m | |
| CEO & Director | 4.9yrs | US$5.82m | 0.27% $ 12.0m | |
| Chief Financial Officer | 2.6yrs | US$2.07m | 0.079% $ 3.5m | |
| Chief Medical Officer | 2.9yrs | US$1.92m | 0.13% $ 5.5m | |
| Chief Technology Officer | 1.1yrs | no data | no data | |
| Vice President of Investor Relations | 1.7yrs | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 2.3yrs | no data | 0.061% $ 2.7m | |
| Vice President of Marketing | 4.3yrs | no data | no data | |
| Vice President of Human Resources | no data | no data | no data | |
| Chief Development Officer | 1.1yrs | US$7.84m | 0.16% $ 7.2m | |
| Vice President of Financial Planning & Chief of Staff to the CEO | no data | no data | no data | |
| Chief Medical Officer | no data | no data | 0.012% $ 545.2k |
2.6yrs
Average Tenure
52yo
Average Age
Experienced Management: IMVT's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairperson of the Board | 4.9yrs | US$2.49m | 0.083% $ 3.7m | |
| CEO & Director | 4.6yrs | US$5.82m | 0.27% $ 12.0m | |
| Independent Director | 4.4yrs | US$291.32k | 0.0098% $ 435.8k | |
| Director | 4.6yrs | US$298.82k | 0% $ 0 | |
| Independent Director | 4.6yrs | US$287.62k | 0.014% $ 609.8k | |
| Independent Director | 4.6yrs | US$290.12k | 0.013% $ 556.2k | |
| Director | 4.3yrs | no data | no data |
4.6yrs
Average Tenure
56yo
Average Age
Experienced Board: IMVT's board of directors are considered experienced (4.6 years average tenure).